PACB - Pacific Biosciences of California - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PACB is currently covered by 13 analysts with an average price target of $2.45. This is a potential upside of $1.53 (166.3%) from yesterday's end of day stock price of $0.92.

Pacific Biosciences of California's activity chart (see below) currently has 68 price targets and 89 ratings on display. The stock rating distribution of PACB is 64.29% BUY and 35.71% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 57.99% with an average time for these price targets to be met of 193.53 days.

Highest price target for PACB is $4, Lowest price target is $1.25, average price target is $2.31.

Most recent stock forecast was given by DAVID WESTENBERG from PIPER SANDLER on 15-May-2025. First documented stock forecast 27-Aug-2015.

Currently out of the existing stock ratings of PACB, 27 are a BUY (64.29%), 15 are a HOLD (35.71%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$1.25

$0.21 (20.19%)

$2

9 days ago
(15-May-2025)

6/9 (66.67%)

$0.19 (17.92%)

154

Buy

$1.8

$0.76 (73.08%)

$2.5

9 days ago
(15-May-2025)

0/3 (0%)

$0.74 (69.81%)

Buy

$3

$1.96 (188.46%)

$3

1 months 14 days ago
(10-Apr-2025)

5/13 (38.46%)

$1.62 (117.39%)

123

Buy

$2

$0.96 (92.31%)

$6

1 months 29 days ago
(25-Mar-2025)

2/5 (40%)

$0.69 (52.67%)

26

Hold

$1.5

$0.46 (44.23%)

$1.75

3 months 6 days ago
(18-Feb-2025)

3/6 (50%)

$-0.35 (-18.92%)

77

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PACB (Pacific Biosciences of California) average time for price targets to be met?

On average it took 193.53 days on average for the stock forecasts to be realized with a an average price target met ratio 57.99

Which analyst has the current highest performing score on PACB (Pacific Biosciences of California) with a proven track record?

STEVEN MAH

Which analyst has the most public recommendations on PACB (Pacific Biosciences of California)?

Steven Mah works at TD COWEN and has 7 price targets and 6 ratings on PACB

Which analyst is the currently most bullish on PACB (Pacific Biosciences of California)?

Steven Mah with highest potential upside - $50.96

Which analyst is the currently most reserved on PACB (Pacific Biosciences of California)?

Doug Schenkel with lowest potential downside - -$0

Pacific Biosciences of California in the News

Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Pacific Biosciences of California (PACB) reported revenue of $37.15 million, down 4.3% over the same period last year. EPS came in at -$0.15, compared to -$0.26 in the year-ago quarter. The reported revenue represents a surprise of +6.15% over the Zacks Consensus Estimate of $35 million. With the consensus...

PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts’ consensus estimates. Is now the time to buy PacBio? Find out in our full research report....
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?